Comparing adrenal venous sampling outcomes in primary aldosteronism with concurrent versus discontinued use of mineralocorticoid receptor antagonist: a randomized-controlled trial
Phase 2
- Conditions
- Patients with a confirmed diagnosis of PA according to the criteria of the Endocrine Society Clinical Practice guideline 2016.Continue MRA, discontinue MRA, Primary aldosteronism, lateralization index, contralateral suppression index
- Registration Number
- TCTR20230908002
- Lead Sponsor
- Faculty of Medicine, Chiang Mai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Patients with a confirmed diagnosis of PA according to the criteria of the Endocrine Society Clinical Practice guideline 2016
2. Be ready and have indications for doing AVS
3. AVS results with a selectivity index confirm that the catheter is in the adrenal vein and AVS results confirm that it is in unilateral form.
4. 20-70 years old
Exclusion Criteria
1. Patients who do not consent to AVS
2. Patients who can skip unilateral adrenalectomy without AVS
2.1 Patients < 35 years old with unilateral adenoma on CT or MRI with obvious PA characteristics (PAC > 30 ng/dL and spontaneously low potassium).
2.2 Patients suspected of adrenal cancer (adrenocortical carcinoma)
3. Patients diagnosed with familial hyperaldosteronism type I and III.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ateralization index 4-8 month after intervention serum aldosterone/cortisol of dominant side, non dominant side ,Contralateral suppression index 4-8 months serum aldosterone/cortisol of non dominant side, IVC
- Secondary Outcome Measures
Name Time Method clinical and biochemical outcome after unilateral adrenalectomy 3 months, 6 months blood pressure, antihypertensive drug, potassium, PAC, DRC